Trial Profile
The phase Ⅱ study of Apatinib in treating patients with advanced/recurrent ovarian cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 02 Jan 2017 New trial record